ErVimmune

ErVimmune is a private, clinical-stage biotech founded in 2019, headquartered in Paris, France, with a lab presence in Lyon. The company is pioneering a novel approach to cancer immunotherapy by targeting HERV-derived antigens, aiming to convert immunologically 'cold' tumors into 'hot' ones responsive to treatment. With a €17 million Series A first closing in early 2026, it is advancing its lead cancer vaccine candidate into clinical development. Its strategy is supported by a proprietary AI and proteomics platform and peer-reviewed scientific validation.

Proprietary AI-driven discovery platform integrating bioinformatics, proteomics, and immunology assays to identify and validate shared, non-conventional tumor antigens derived from Human Endogenous Retroviruses (HERVs).

ErVimmune competes in the broad cancer vaccine and cell therapy arena, specifically against companies developing therapies for cold tumors (e.g., via innate immune activation, novel antigen targets). Its unique differentiator is the focus on HERV-derived shared antigens, a niche with few clinical-stage competitors, though it faces indirect competition from all modalities aiming to overcome immunosuppressive tumor microenvironments.